Urolithiasis associated with topiramate

Scott Eggener, Samuel C. Kim, Herbert M. User, Joseph Pazona, Robert B. Nadler*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Objective: Topiramate is a sulfamate-substituted monosaccharide anticonvulsant used as adjunctive therapy for intractable refractory seizures. It is report a case of topiramate-induced urolithiasis. Case Report: A 35-year-old man presented with acute, right-sided, colicky flank pain. He denied hematuria or dysuria. He was in use of phenytoin, risperidone, phenobarbital, and topiramate. The total daily dose of topiramate was 375 mg. A CT scan showed a 7 × 1 mm curvilinear density at the right ureterovesical junction with proximal hydrouretronephrosis. He was managed with rigid ureteroscopic stone extraction and the calculus metabolic analysis revealed the stone was composed of carbonate apatite (70%), calcium oxalate dihydrate (20%), and calcium oxalate monohydrate (10%). Comments: The present case typifies many features of topiramate-induced urolithiasis. Those who care for patients with urinary stone disease should be aware of this association.

Original languageEnglish (US)
Pages (from-to)29-30
Number of pages2
JournalInternational Braz J Urol
Volume30
Issue number1
DOIs
StatePublished - 2004
Externally publishedYes

Keywords

  • Acids
  • Adverse effects
  • Anticonvulsants
  • Metabolism
  • Urolithiasis

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Urolithiasis associated with topiramate'. Together they form a unique fingerprint.

Cite this